$CVS
CVS HEALTH Corp

2022 Q4 Form 10-Q Financial Statement

#000006480322000038 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $83.85B $81.16B
YoY Change 9.45% 9.98%
Cost Of Revenue $51.73B $50.37B
YoY Change 11.54% 11.89%
Gross Profit $32.12B $30.79B
YoY Change 6.26% 6.99%
Gross Profit Margin 38.31% 37.94%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $28.39B $27.03B
YoY Change 6.69% 6.94%
Operating Profit $3.729B -$3.931B
YoY Change 3.07% -228.42%
Interest Expense -$552.0M $566.0M
YoY Change -9.21% -5.98%
% of Operating Profit -14.8%
Other Income/Expense, Net $43.00M $41.00M
YoY Change 13.16% -16.33%
Pretax Income $3.109B -$4.456B
YoY Change 98.03% -307.74%
Income Tax $809.0M -$1.047B
% Of Pretax Income 26.02%
Net Earnings $2.302B -$3.416B
YoY Change 76.26% -313.77%
Net Earnings / Revenue 2.75% -4.21%
Basic Earnings Per Share -$2.60
Diluted Earnings Per Share $1.74 -$2.60
COMMON SHARES
Basic Shares Outstanding 1.314B shares 1.313B shares
Diluted Shares Outstanding 1.315B shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.72B $19.99B
YoY Change 25.53% 55.67%
Cash & Equivalents $12.95B $17.20B
Short-Term Investments $2.778B $2.792B
Other Short-Term Assets $2.685B $2.479B
YoY Change -49.26% -53.39%
Inventory $19.09B $18.06B
Prepaid Expenses
Receivables $27.28B $26.32B
Other Receivables $3.449B $2.647B
Total Short-Term Assets $65.68B $68.34B
YoY Change 9.46% 12.33%
LONG-TERM ASSETS
Property, Plant & Equipment $12.87B $12.63B
YoY Change -0.18% -1.14%
Goodwill $78.15B $78.09B
YoY Change -1.23% -1.31%
Intangibles $24.75B $25.16B
YoY Change -14.72% -14.85%
Long-Term Investments $21.10B $20.57B
YoY Change -8.38% -8.07%
Other Assets $4.620B $4.849B
YoY Change -1.99% 3.3%
Total Long-Term Assets $162.6B $162.9B
YoY Change -6.01% -6.42%
TOTAL ASSETS
Total Short-Term Assets $65.68B $68.34B
Total Long-Term Assets $162.6B $162.9B
Total Assets $228.3B $231.2B
YoY Change -2.03% -1.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.67B $43.44B
YoY Change 15.47% 10.06%
Accrued Expenses $18.75B $19.42B
YoY Change 6.08% 20.34%
Deferred Revenue $71.00M $74.00M
YoY Change -18.39% -5.13%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.778B $1.363B
YoY Change -57.72% -12.68%
Total Short-Term Liabilities $69.74B $72.41B
YoY Change 2.84% 11.9%
LONG-TERM LIABILITIES
Long-Term Debt $50.48B $50.85B
YoY Change -2.88% -10.53%
Other Long-Term Liabilities $6.732B $6.769B
YoY Change 253.57% 193.03%
Total Long-Term Liabilities $6.732B $6.769B
YoY Change 253.57% 193.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.74B $72.41B
Total Long-Term Liabilities $6.732B $6.769B
Total Liabilities $157.0B $160.2B
YoY Change -0.42% -0.04%
SHAREHOLDERS EQUITY
Retained Earnings $56.15B $54.57B
YoY Change 2.26% 0.57%
Common Stock $18.00M $18.00M
YoY Change 5.88% 5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.86B $30.33B
YoY Change 13.08% 7.67%
Treasury Stock Shares 458.0M shares 442.0M shares
Shareholders Equity $71.02B $70.68B
YoY Change
Total Liabilities & Shareholders Equity $228.3B $231.2B
YoY Change -2.03% -1.57%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $2.302B -$3.416B
YoY Change 76.26% -313.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.952B $9.123B
YoY Change -148.74% 65.24%
INVESTING ACTIVITIES
Capital Expenditures $688.0M -$580.0M
YoY Change -215.24% -4.61%
Acquisitions
YoY Change
Other Investing Activities $569.0M -$225.0M
YoY Change -167.5% -5.86%
Cash From Investing Activities -$119.0M -$805.0M
YoY Change -91.74% -4.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.187B -3.218B
YoY Change -22.75% 63.6%
NET CHANGE
Cash From Operating Activities -1.952B 9.123B
Cash From Investing Activities -119.0M -805.0M
Cash From Financing Activities -2.187B -3.218B
Net Change In Cash -4.258B 5.100B
YoY Change 1500.75% 88.4%
FREE CASH FLOW
Cash From Operating Activities -$1.952B $9.123B
Capital Expenditures $688.0M -$580.0M
Free Cash Flow -$2.640B $9.703B
YoY Change -157.37% 58.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2022Q3 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-01011
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-22000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-2000000 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2574000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 usd
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1313966912 shares
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive,
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket,
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
21003000000 usd
CY2021Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
18984000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
63894000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
56927000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
832000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2021Q3 us-gaap Revenues
Revenues
73794000000 usd
us-gaap Revenues
Revenues
238621000000 usd
us-gaap Revenues
Revenues
215507000000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
50365000000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45011000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
145164000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
129425000000 usd
CY2022Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
17419000000 usd
CY2021Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
16081000000 usd
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
52976000000 usd
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
47686000000 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5220000000 usd
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5704000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2480000000 usd
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
CY2022Q3 cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
9606000000 usd
CY2021Q3 cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
9210000000 usd
cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
28128000000 usd
cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
27001000000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
85090000000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
70733000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
234493000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
204543000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3931000000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3061000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4128000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10964000000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
566000000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
602000000 usd
us-gaap Interest Expense
InterestExpense
1735000000 usd
us-gaap Interest Expense
InterestExpense
1895000000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
126000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
144000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4456000000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2145000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2519000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8850000000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1047000000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
558000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
654000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2248000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3409000000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 usd
us-gaap Profit Loss
ProfitLoss
1865000000 usd
us-gaap Profit Loss
ProfitLoss
6602000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7000000 usd
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3416000000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
1598000000 usd
us-gaap Net Income Loss
NetIncomeLoss
1847000000 usd
us-gaap Net Income Loss
NetIncomeLoss
6604000000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.60
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.01
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3409000000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.60
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.98
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1321000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1313000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1318000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1329000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1324000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1326000000 shares
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.55
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-623000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-73000000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 usd
us-gaap Profit Loss
ProfitLoss
1865000000 usd
us-gaap Profit Loss
ProfitLoss
6602000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2591000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-310000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
8000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-22000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-2000000 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2574000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4030000000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1494000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-709000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6265000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7000000 usd
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4037000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4030000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-709000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7000000 usd
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4037000000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1505000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-727000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6267000000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17197000000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26317000000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
17760000000 usd
CY2022Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
1498000000 usd
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2479000000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1505000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-727000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6267000000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17197000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9408000000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
2792000000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3117000000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26317000000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24431000000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
18058000000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
17760000000 usd
CY2022Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
1498000000 usd
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2479000000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5292000000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
68341000000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5292000000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
68341000000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
60008000000 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
20565000000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
23025000000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12626000000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12896000000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18270000000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19122000000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25157000000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29026000000 usd
CY2022Q3 us-gaap Separate Account Assets
SeparateAccountAssets
3318000000 usd
CY2021Q4 us-gaap Separate Account Assets
SeparateAccountAssets
5087000000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4849000000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4714000000 usd
CY2022Q3 us-gaap Assets
Assets
231212000000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
60008000000 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
20565000000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12896000000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18270000000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19122000000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
78086000000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
79121000000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25157000000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29026000000 usd
CY2022Q3 us-gaap Separate Account Assets
SeparateAccountAssets
3318000000 usd
CY2021Q4 us-gaap Separate Account Assets
SeparateAccountAssets
5087000000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4849000000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4714000000 usd
CY2022Q3 us-gaap Assets
Assets
231212000000 usd
CY2021Q4 us-gaap Assets
Assets
232999000000 usd
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
13925000000 usd
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
12544000000 usd
CY2022Q3 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
19161000000 usd
CY2021Q4 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
17330000000 usd
CY2022Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
10351000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
8808000000 usd
CY2022Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1642000000 usd
CY2021Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
4301000000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17670000000 usd
CY2021Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1303000000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1687000000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1646000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1363000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4205000000 usd
CY2022Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
296000000 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
72409000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
8808000000 usd
CY2022Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1642000000 usd
CY2021Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
4301000000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19423000000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17670000000 usd
CY2022Q3 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
4561000000 usd
CY2021Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1303000000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1687000000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1646000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1363000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4205000000 usd
CY2022Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
296000000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
72409000000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67807000000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17174000000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18177000000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67807000000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17174000000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18177000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
50848000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
51971000000 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3508000000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6270000000 usd
CY2022Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3318000000 usd
CY2021Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
5087000000 usd
CY2022Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
6175000000 usd
CY2021Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
6402000000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6769000000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1904000000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
160201000000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
157618000000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
50848000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
51971000000 usd
CY2022Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3318000000 usd
CY2021Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
5087000000 usd
CY2022Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
6175000000 usd
CY2021Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
6402000000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6769000000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1904000000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
160201000000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
157618000000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1757000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1315000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1757000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1744000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1322000000 shares
CY2021Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
47377000000 usd
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
442000000 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
422000000 shares
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
30326000000 usd
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1744000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1322000000 shares
CY2022Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48047000000 usd
CY2021Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
47377000000 usd
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
442000000 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
422000000 shares
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
30326000000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
28173000000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
54571000000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
54906000000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1609000000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
965000000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70683000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
75075000000 usd
CY2022Q3 us-gaap Minority Interest
MinorityInterest
328000000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
28173000000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
54571000000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
54906000000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1609000000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
965000000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70683000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
75075000000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
306000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75381000000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
231212000000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232999000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
235395000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
209104000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
138785000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
122129000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
51434000000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
306000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71011000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75381000000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
231212000000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232999000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
235395000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
209104000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
138785000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
122129000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
46965000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
22368000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
21840000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
327000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
582000000 usd
us-gaap Interest Paid Net
InterestPaidNet
1936000000 usd
us-gaap Interest Paid Net
InterestPaidNet
2095000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
46965000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
22368000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
21840000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
327000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
582000000 usd
us-gaap Interest Paid Net
InterestPaidNet
2095000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2397000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5535000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5559000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6439000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2039000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
131000000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
2808000000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-74000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3070000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2397000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
18129000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5535000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5559000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6439000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
7417000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2039000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1923000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
131000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
135000000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
2808000000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
0 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
-1928000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-74000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-95000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4928000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3821000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
987000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4195000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7823000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2188000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1965000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
510000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
161000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8329000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-95000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4928000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3821000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
987000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7823000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1965000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
510000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
337000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
161000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-119000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
80000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8329000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8442000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4872000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8442000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1997000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12691000000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11043000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17563000000 usd
us-gaap Profit Loss
ProfitLoss
6602000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3397000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
341000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
346000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4872000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1997000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12691000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17563000000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13040000000 usd
us-gaap Profit Loss
ProfitLoss
1865000000 usd
us-gaap Profit Loss
ProfitLoss
6602000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3198000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3397000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
341000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
346000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-2250000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-645000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2009000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3504000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
415000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1097000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
311000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3350000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
348000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7377000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1940000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75381000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-2250000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-645000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2009000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3504000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
415000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1097000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
311000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
88000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3350000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3973000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4687000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
348000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7377000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1940000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
18129000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75381000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2313000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1155000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000000 usd
CY2022Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
1972000000 usd
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
730000000 usd
CY2022Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
3000000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74140000000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
2961000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-798000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000000 usd
CY2022Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
267000000 usd
CY2022Q2 us-gaap Dividends Common Stock
DividendsCommonStock
729000000 usd
CY2022Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
2000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75506000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3409000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2313000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000000 usd
CY2022Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
3000000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74140000000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
2961000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-798000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000000 usd
CY2022Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
267000000 usd
CY2022Q2 us-gaap Dividends Common Stock
DividendsCommonStock
729000000 usd
CY2022Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
2000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75506000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3409000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000000 usd
CY2022Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
86000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000000 usd
CY2022Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-1000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71011000000 usd
CY2021Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69701000000 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2224000000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-392000000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000000 usd
CY2021Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
76000000 usd
CY2022Q3 us-gaap Dividends Common Stock
DividendsCommonStock
723000000 usd
CY2022Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-1000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71011000000 usd
CY2021Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69701000000 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2224000000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-392000000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000000 usd
CY2021Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
76000000 usd
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
660000000 usd
CY2021Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
1000000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71164000000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
2791000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
148000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
268000000 usd
CY2021Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
150000000 usd
CY2021Q2 us-gaap Dividends Common Stock
DividendsCommonStock
655000000 usd
CY2021Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-1000000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73565000000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
138000000 usd
CY2021Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
86000000 usd
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
660000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
148000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
268000000 usd
CY2021Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
150000000 usd
CY2021Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-1000000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73565000000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
138000000 usd
CY2021Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
86000000 usd
CY2021Q3 us-gaap Dividends Common Stock
DividendsCommonStock
665000000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74618000000 usd
CY2021Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2021Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2021Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2020Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2020Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74618000000 usd
CY2021Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2021Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2020Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2020Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2022Q3 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
110000000 people
CY2022Q3 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
1000000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2021Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2022Q3 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
110000000 people
CY2022Q3 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
1000000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17197000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9408000000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
151000000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17197000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9408000000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9826000000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
151000000 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
3065000000 usd
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
2996000000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
215000000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
218000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17563000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12691000000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13040000000 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
3065000000 usd
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
2996000000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
215000000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
218000000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
218000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17563000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12691000000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13040000000 usd
CY2022Q3 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
13534000000 usd
CY2022Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2368000000 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3389000000 usd
CY2022Q3 cvs Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale
AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
26565000000 usd
CY2021Q4 cvs Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale
AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
24431000000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
344000000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
339000000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8016000000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7932000000 usd
CY2022Q3 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
13534000000 usd
CY2021Q4 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
10573000000 usd
CY2022Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2368000000 usd
CY2021Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2537000000 usd
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2647000000 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3389000000 usd
CY2022Q3 cvs Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale
AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
26565000000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
344000000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
339000000 usd
CY2022Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
22000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 usd
CY2021Q3 us-gaap Revenues
Revenues
73794000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Revenues
Revenues
238621000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
832000000 usd
us-gaap Revenues
Revenues
215507000000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8016000000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7932000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
250000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 usd
CY2021Q3 us-gaap Revenues
Revenues
73794000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Revenues
Revenues
238621000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
832000000 usd
us-gaap Revenues
Revenues
215507000000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8016000000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7932000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
286000000 usd
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
263000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87000000 usd
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
71000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
250000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
286000000 usd
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
263000000 usd
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
279000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74000000 usd
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78000000 usd
CY2021Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
16000000 usd
CY2022Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
16000000 usd
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
47000000 usd
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
35000000 usd
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
279000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74000000 usd
CY2021Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
16000000 usd
CY2022Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
16000000 usd
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
47000000 usd
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
35000000 usd
CY2022Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
22000000 usd
CY2021Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
20000000 usd
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
66000000 usd
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
57000000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
2792000000 usd
CY2022Q3 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
20583000000 usd
CY2022Q3 us-gaap Investments
Investments
23375000000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3117000000 usd
CY2021Q4 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
23025000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
17000000 usd
CY2021Q4 us-gaap Investments
Investments
26142000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22248000000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
2792000000 usd
CY2022Q3 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
20583000000 usd
CY2022Q3 us-gaap Investments
Investments
23375000000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3117000000 usd
CY2021Q4 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
23025000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22239000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2225000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20040000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22174000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1172000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
106000000 usd
CY2021Q4 us-gaap Investments
Investments
26142000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22248000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
9000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22239000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2225000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20040000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22174000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1172000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1299000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23240000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1299000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1288000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
6704000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6260000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4980000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4347000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
4403000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3733000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22239000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20040000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1288000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
6704000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6260000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4980000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4347000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
4403000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3733000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22239000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20040000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1786000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
1609 security
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
2489000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
439000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
12971 security
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
19456000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2225000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
11362 security
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
16967000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1786000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
1609 security
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
2489000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
19456000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
3700 security
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6800000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
84000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
317 security
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
584000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
22000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
4017 security
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
7384000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
106000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
1211000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
3700 security
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6800000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
84000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
317 security
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
584000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
22000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
4017 security
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
7384000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
106000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
1211000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
14000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
6018000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
451000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
4267000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
637000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
3571000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
6018000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
637000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
3571000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
677000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
19456000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2225000000 usd
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
322000000 usd
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
279000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
827000000 usd
CY2022Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
CY2021Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
CY2022Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
677000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
19456000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2225000000 usd
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
279000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
827000000 usd
CY2022Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
73000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
822000000 usd
CY2022Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
CY2021Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
29000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
28000000 usd
CY2022Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
311000000 usd
CY2021Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
268000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
798000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
794000000 usd
CY2022Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-110000000 usd
CY2022Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
311000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
798000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
794000000 usd
CY2022Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-110000000 usd
CY2021Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-22000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-283000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
38000000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
201000000 usd
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
246000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
515000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
832000000 usd
CY2022Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
121000000 usd
CY2021Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
3000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
35000000 usd
CY2021Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2021Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-22000000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
201000000 usd
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
246000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
515000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
832000000 usd
CY2022Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
121000000 usd
CY2021Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
3000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
35000000 usd
CY2021Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2022Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
593000000 usd
CY2022Q3 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
68 lease
CY2021Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
668000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3556000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2935000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
3000000 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
19000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
20000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
135000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2021Q4 cvs Long Term Debt Gross And Lease Obligation
LongTermDebtGrossAndLeaseObligation
56743000000 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
204000000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
219000000 usd
CY2022Q3 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
716000000 usd
CY2021Q4 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
786000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
52214000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
56176000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1363000000 usd
CY2021Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
668000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3556000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2935000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
3000000 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
19000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
20000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
61000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
28000000 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
135000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
12000000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
29000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
56176000000 usd
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,346 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div>(1)Total incurred health care costs for the nine months ended September 30, 2022 and 2021 in the table above exclude (i) $5 million and $1 million, respectively, for premium deficiency reserves related to the Company’s Medicaid products, (ii) $56 million and $45 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and (iii) $274 million and $168 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
CY2022Q3 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
7900000000 usd
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1437000000 usd
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1300000000 usd
CY2022Q3 cvs Long Term Debt Gross And Lease Obligation
LongTermDebtGrossAndLeaseObligation
52726000000 usd
CY2021Q4 cvs Long Term Debt Gross And Lease Obligation
LongTermDebtGrossAndLeaseObligation
56743000000 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
204000000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
219000000 usd
CY2022Q3 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
716000000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1363000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4205000000 usd
CY2022Q3 cvs Long Term Debt And Lease Obligation Including Liabilities Held For Sale
LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
50851000000 usd
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.55
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-621000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2574000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000 shares
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3416000000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1598000000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4205000000 usd
CY2022Q3 cvs Long Term Debt And Lease Obligation Including Liabilities Held For Sale
LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
50851000000 usd
CY2021Q4 cvs Long Term Debt And Lease Obligation Including Liabilities Held For Sale
LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
51971000000 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.55
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2574000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000 shares
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3416000000 usd
CY2021Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
73548000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1598000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1847000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6604000000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1313000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1318000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1329000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1324000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1326000000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.60
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.60
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.40
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1847000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6604000000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1321000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1313000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1318000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1329000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1324000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1326000000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.60
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
CY2022Q3 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
68 lease
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4233000000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.98
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 usd
CY2021Q3 us-gaap Revenues
Revenues
73794000000 usd
CY2012 cvs Loss Contingency Audit Methodology Sample Size
LossContingencyAuditMethodologySampleSize
200 member
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2022Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
80958000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4233000000 usd
CY2021Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
73548000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 usd
CY2021Q3 us-gaap Revenues
Revenues
73794000000 usd
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
238106000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Revenues
Revenues
238621000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13526000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
214675000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
238106000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
214675000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
832000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3931000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10964000000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
464000000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
561000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1398000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1730000000 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5220000000 usd
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5704000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2480000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
832000000 usd
us-gaap Revenues
Revenues
215507000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3931000000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3061000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4128000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10964000000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
464000000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
561000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1398000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1730000000 usd
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5704000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2480000000 usd
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2021Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
0 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
101000000 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
CY2022Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
CY2021Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2021Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
0 usd
CY2021Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
20000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
0 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
101000000 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 usd
CY2022Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
CY2021Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 usd
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
61000000 usd
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4233000000 usd
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13526000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 usd
CY2021Q2 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
61000000 usd
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
61000000 usd
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13526000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 usd
CY2021Q2 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
61000000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000064803-22-000038-index-headers.html Edgar Link pending
0000064803-22-000038-index.html Edgar Link pending
0000064803-22-000038.txt Edgar Link pending
0000064803-22-000038-xbrl.zip Edgar Link pending
a09302022ex151.htm Edgar Link pending
a09302022ex311.htm Edgar Link pending
a09302022ex312.htm Edgar Link pending
a09302022ex321.htm Edgar Link pending
a09302022ex322.htm Edgar Link pending
cvs-20220930.htm Edgar Link pending
cvs-20220930.xsd Edgar Link pending
cvs-20220930_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
cvs-20220930_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvs-20220930_lab.xml Edgar Link unprocessable
cvs-20220930_pre.xml Edgar Link unprocessable
cvs-20220930_cal.xml Edgar Link unprocessable
cvs-20220930_def.xml Edgar Link unprocessable